Featured Research

from universities, journals, and other organizations

Combination therapy for heart failure does not reduce risk of CV death or rehospitalization

Date:
March 11, 2013
Source:
American Medical Association (AMA)
Summary:
Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a new study.

Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA.

Related Articles


The study is being released early to coincide with its presentation at the American College of Cardiology's annual Scientific Sessions.

"Inhibition of the renin-angiotensin-aldosterone system [RAAS; the regulation of sodium balance, fluid volume, and blood pressure by secretion of renin in response to reduced perfusion of the kidney] has long been recognized as a life-prolonging therapy for patients with chronic heart failure with reduced LVEF, and angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) are recommended by all major national guidelines. However, although the benefits of these treatments are undisputed, these agents induce a compensatory increase in renin [an enzyme secreted by the kidneys] and downstream RAAS intermediaries that may partially offset RAAS blocking effects," according to background information in the article.

The direct renin inhibitors (DRIs) represent another pharmacologically distinct method for RAAS blockade. Aliskiren, an orally active DRI, has demonstrated a favorable hemodynamic and neurohormonal profile in patients with HF. "Despite current evidence-based therapies, patients with hospitalization for HF (HHF) face postdischarge mortality and rehospitalization rates as high as 15 percent and 30 percent, respectively, within 60 to 90 days. Incomplete suppression of the RAAS may contribute to the exceptionally high postdischarge event rate," the authors write.

Mihai Gheorghiade, M.D., of the Northwestern University Feinberg School of Medicine, Chicago, and colleagues conducted a study (the ASTRONAUT randomized trial) to examine whether the addition of a DRI (aliskiren) to standard therapy would improve long-term outcomes in HHF patients. The study included hemodynamically stable HHF patients a median (midpoint) 5 days after admission who met certain criteria. Patients were recruited from 316 sites across North and South America, Europe, and Asia between May 2009 and December 2011. The follow-up period ended in July 2012.

All patients received 150 mg (increased to 300 mg as tolerated) of aliskiren or placebo daily, in addition to standard therapy. The study drug was continued after discharge for a median 11.3 months.

The final group for efficacy analyses included 1,615 patients (808 assigned to aliskiren, 807 assigned to placebo). At randomization, patients were receiving diuretics (95.9 percent), beta-blockers (82.5 percent), ACE inhibitors or ARBs (84.2 percent), and MRAs (57.0 percent).There were no major differences between the 2 treatment groups at the time of randomization. The average age was 65 years.

"In total, 24.9 percent of patients receiving aliskiren (77 cardiovascular [CV] deaths, 153 HF hospitalizations) and 26.5 percent of patients receiving placebo (85 CV deaths, 166 HF rehospitalizations) experienced the primary end point [cardiovascular death or HF rehospitalization] at 6 months. At 12 months, the event rates were 35.0 percent for the aliskiren group (126 CV deaths, 212 HF rehospitalizations) and 37.3 percent for the placebo group (137 CV deaths, 224 HF rehospitalizations)," the authors write.

During the overall follow-up period (ranging from 0.1 to 31.2 months), the total hospitalization rates (i.e., percentage of patients hospitalized for any reason) in the aliskiren and placebo groups were 48.1 percent and 49.1 percent, respectively. The HF hospitalization rates within 12 months were 26.2 percent in the aliskiren group and 27.8 percent in the placebo group.

The researchers also found that the rates of hyperkalemia (higher than normal levels of potassium in the circulating blood), hypotension, and renal impairment/renal failure were higher in the aliskiren group compared with placebo.

"The results of the ASTRONAUT study do not support the routine administration of aliskiren, in addition to evidence-based therapy, to patients hospitalized for worsening chronic HF. Subgroup analysis is consistent with previous reports of poor outcomes with the use of aliskiren in patients with diabetes mellitus [DM] already taking RAAS inhibitors. Further investigations are needed to evaluate the effects of renin inhibition in a large cohort of HHF patients that excludes patients with DM," the authors conclude.


Story Source:

The above story is based on materials provided by American Medical Association (AMA). Note: Materials may be edited for content and length.


Journal Reference:

  1. Gheorghiade M, Bφhm M, Greene SJ, et al. Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure: The ASTRONAUT Randomized Trial. JAMA, 2013; DOI: 10.1001/jama.2013.1954

Cite This Page:

American Medical Association (AMA). "Combination therapy for heart failure does not reduce risk of CV death or rehospitalization." ScienceDaily. ScienceDaily, 11 March 2013. <www.sciencedaily.com/releases/2013/03/130311150821.htm>.
American Medical Association (AMA). (2013, March 11). Combination therapy for heart failure does not reduce risk of CV death or rehospitalization. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2013/03/130311150821.htm
American Medical Association (AMA). "Combination therapy for heart failure does not reduce risk of CV death or rehospitalization." ScienceDaily. www.sciencedaily.com/releases/2013/03/130311150821.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins